-
[show abstract]
[hide abstract]
ABSTRACT: The human EGF receptor (EGFR or HER) family and its cognate ligands contribute significantly to the aggressiveness of many human malignancies, and are therefore therapeutic targets with great clinical potential.
Currently approved single-targeted agents, like mAbs, (e.g., trastuzumab, cetuximab, or pertuzumab) or small-molecule tyrosine kinase inhibitors (TKIs, e.g., gefinitib and erlotinib), are limited by their exquisite specificity (mAbs) or lack thereof (TKIs). Therefore, therapeutics are needed that target multiple HER family members and HER ligands to circumvent these limitations.
We summarize therapeutic mechanisms of action, analyze tumor resistance to current anti-HER therapies, and introduce a novel pan-HER ligand sequestering agent for cancer treatment.
RB200, a bispecific (EGFR/HER3) ligand binding trap, has been developed to address the need for a pan-HER therapy in human cancer.
Expert opinion on biological therapy 02/2009; 9(1):97-110. · 3.22 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The human epidermal growth factor (EGF) receptor (HER) family members cooperate in malignancy. Of this family, HER2 does not bind growth factors and HER3 does not encode an active tyrosine kinase. This diversity creates difficulty in creating pan-specific therapeutic HER family inhibitors. We have identified single amino acid changes in epidermal growth factor receptor (EGFR) and HER3 which create high affinity sequestration of the cognate ligands, and may be used as receptor decoys to downregulate aberrant HER family activity. In silico modeling and high throughput mutagenesis were utilized to identify receptor mutants with very high ligand binding activity. A single mutation (T15S; EGFR subdomain I) enhanced affinity for EGF (two-fold), TGF-alpha (twenty-six-fold), and heparin-binding (HB)-EGF (six-fold). This indicates that T15 is an important, previously undescribed, negative regulatory amino acid for EGFR ligand binding. Another mutation (Y246A; HER 3 subdomain II) enhanced neuregulin (NRG)1-beta binding eight-fold, probably by interfering with subdomain II-IV interactions. Further work revealed that the HER3 subunit of an EGFR:HER3 heterodimer suppresses EGFR ligand binding. Optimization required reversing this suppression by mutation of the EGFR tether domain (G564A; subdomain IV). This mutation resulted in enhanced ligand binding (EGF, ten-fold; TGF-alpha, thirty-four-fold; HB-EGF, seventeen-fold; NRG1-beta, thirty-one-fold). This increased ligand binding was reflected in improved inhibition of in vitro tumor cell proliferation and tumor suppression in a human non-small cell lung cancer xenograft model. In conclusion, amino acid substitutions were identified in the EGFR and HER3 ECDs that enhance ligand affinity, potentially enabling a pan-specific therapeutic approach for downregulating the HER family in cancer.
Molecular Medicine 12/2008; 15(1-2):11-20. · 3.76 Impact Factor
-
Jay Sarup,
Pei Jin,
Lisa Turin,
Xiaomei Bai,
Malgorzata Beryt, Cathleen Brdlik,
Jeffrey N Higaki,
Brett Jorgensen,
Francis W Lau,
Peter Lindley,
Jim Liu,
Irene Ni,
James Rozzelle,
Rajendra Kumari,
Susan A Watson,
Juan Zhang,
H Michael Shepard
[show abstract]
[hide abstract]
ABSTRACT: All four members of the human epidermal growth factor (EGF) receptor (HER) family are implicated in human cancers. Although efficacious in a subset of patients, resistance to single-targeted anti-HER therapy [i.e., cetuximab (Erbitux) and trastuzumab (Herceptin)] is often associated with coexpression of other HER family members. This may be overcome by a HER ligand binding molecule that sequesters multiple EGF-like ligands, preventing ligand-dependent receptor activation. Toward this end, we have combined the HER-1/EGFR and HER-3 ligand binding domains, dimerized with fusion of an Fc fragment of human IgG1. This resulted in a mixture of HER-1/Fc homodimer (HFD100), HER-3/Fc homodimer (HFD300), and HER-1/Fc:HER-3/Fc heterodimer (RB200), also termed Hermodulins. The purified first-generation RB200 bound EGF and neuregulin 1 (NRG1)-beta1 ligands, determined by cross-linking and direct binding studies. The binding affinity for both was approximately 10 nmol/L by dissociation-enhanced lanthanide fluorescence immunoassay using europium (Eu)-labeled ligands. Competition studies with RB200 using Eu-EGF or Eu-NRG1-beta1 revealed that RB200 bound HER-1 ligands, including transforming growth factor-alpha and heparin-binding EGF, and HER-3 ligands NRG1-alpha and NRG1-beta3. RB200 inhibited EGF- and NRG1-beta1-stimulated tyrosine phosphorylation of HER family proteins, proliferation of a diverse range of tumor cells in monolayer cell growth assays, tumor cell proliferation as a single agent and in synergy with tyrosine kinase inhibitors, lysophosphatidic acid-stimulated cell proliferation, and tumor growth in two human tumor xenograft nude mouse models. Taken together, the data reveal that RB200 has the potential to sequester multiple HER ligands and interfere with signaling by HER-1, HER-2, and HER-3.
Molecular Cancer Therapeutics 11/2008; 7(10):3223-36. · 5.23 Impact Factor
